Leonardino (Dino) Digma
@leonardinosaur
Followers
204
Following
2K
Media
16
Statuses
101
PGY-2, neurology, neuroscience, imaging, cognition, neurodegenerative diseases ðŸ§
California
Joined September 2013
A #Stanford_Medicine neurologist explains why a trio of closely related drugs all aimed at treating #Alzheimers_disease -- while so promising in theory --don’t appear to be helping patients much if at all. #plaque_attack_fail
https://t.co/O4Bs2k78AJ
med.stanford.edu
A few closely related drugs, all squarely aimed at treating Alzheimer's disease, have served up what can be charitably described as a lackadaisical performance. Stanford Medicine neurologist Mike...
1
5
5
Thank you @brucegoldman for highlighting and nicely summarizing our recent commentary on the limitations of recent anti-amyloid trials. https://t.co/sVfxJ3UbQm
med.stanford.edu
A few closely related drugs, all squarely aimed at treating Alzheimer's disease, have served up what can be charitably described as a lackadaisical performance. Stanford Medicine neurologist Mike...
0
1
3
If you’re at #ADPD2024 and curious about how Amantadine works in PD, please stop by either today or tomorrow at poster 454. Great meeting so far in Lisbon!
4
4
28
0
2
14
Another month of wards in the books! Feeling grateful to have gotten to work with the best senior (@EmilyLChu) best co-intern (@XC_Cortez) and best med student (@MedMusicMel) @StanfordMedRes
0
1
13
Great piece in @journal_ad from @leonardinosaur @joe__winer and Michael Greicius from Stanford on functional unblinding, amyloid removal as a surrogate, and data transparency. Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies https://t.co/QCuhiFwbVW
pubmed.ncbi.nlm.nih.gov
With the FDA approval of aducanumab and lecanemab, and with the recent statistically significant phase 3 clinical trial for donanemab, there is growing enthusiasm for anti-amyloid antibodies in the...
1
1
6
Our commentary on some of the yet unaddressed limitations of the recent anti-amyloid therapies/trials is now out in @journal_ad !! #EndAlz #Alzheimers #ADRD #amyloid #tau #HAI2024
https://t.co/95asY3wjIO
journals.sagepub.com
With the FDA approval of aducanumab and lecanemab, and with the recent statistically significant phase 3 clinical trial for donanemab, there is growing enthusia...
0
0
2
S/p ten (10) day stretch to cap off another month on the @StanfordMedRes wards. Tough to be away from friends/fam over the holidays, but ‘twas nice working with and getting to know my future @Stanford_Neuro co-res Akshara!
0
0
17
My newest project with @PaLab_UCSD exploring the role of cerebrovascular reactivity in developing mild cognitive impairment is now out in @alzdemjournals!🧠https://t.co/H5RBSGGhfu
alz-journals.onlinelibrary.wiley.com
INTRODUCTION Vascular risk factors contribute to cognitive decline suggesting that maintaining cerebrovascular health could reduce dementia risk. The objective of this study is to evaluate the...
1
3
4
An interesting and relevant piece worth reading, by my postdoc mentor Mike Greicius: "Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies" https://t.co/YNzmdJqKHB
0
3
12
Is it possible to cure #AlzheimersDisease? The press has been so enthusiastic about anti-amyloid antibodies, but are they really improving patients? In this @arxiv lead by my P.I. Michael Greicius, some doubts still remain. 👉 https://t.co/EZ50Yw9p7R
@StanfordMed @Stanford_Neuro
1
8
24
Check out Dino's (@leonardinosaur) excellent and important new piece on anti-amyloid therapies, written with Mike Greicius
With #CTAD23 happening, it is an exciting week for the AD field. To contribute to the discussion, we (I, @joe__winer, and Mike Greicius) wanted to highlight three observations regarding recent anti-amyloid clinical trials: https://t.co/2yNv4UZ9PJ
0
2
12
Wow! Some very contentious statements therein. Worth a read!
With #CTAD23 happening, it is an exciting week for the AD field. To contribute to the discussion, we (I, @joe__winer, and Mike Greicius) wanted to highlight three observations regarding recent anti-amyloid clinical trials: https://t.co/2yNv4UZ9PJ
0
1
5
With #CTAD23 happening, it is an exciting week for the AD field. To contribute to the discussion, we (I, @joe__winer, and Mike Greicius) wanted to highlight three observations regarding recent anti-amyloid clinical trials: https://t.co/2yNv4UZ9PJ
arxiv.org
Alzheimer's disease (AD) is a prevalent, progressive, and ultimately fatal neurodegenerative disorder that is defined pathologically by the accumulation of amyloid plaques and tau neurofibrillary...
2
4
13
0
0
1
Looking forward to digging into these associations further. Feel free to reach out if you have any questions or want a higher resolution version of the poster.
1
0
1
An alternative interpretation however is that inability to adhere to exercise may simply be an indicator of any underlying degenerative process.
1
0
1
I think the data are compatible with a couple different interpretions. First, amount of exercise, rather than type, may be protective against degenerative processes. Further, the beneficial effect of exercise may be discernible prior to being discernible of measures of cog/fxn.
1
0
1
We found that higher exercise adherence (more exercise sessions completed during the trial) was associated with slower atrophy and slower dilation of the lat ventricles. However, exercise adherence was not associated with change in functional or cognitive outcomes.
1
0
1